PharmaMar SAThe U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy with atezolizumab, carboplatin and etoposide.
Tag Archive for: PharmaMar
The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.